Beats / 98 priced constituents
hardware
An equal-weight index of the priced names on this beat, rebuilt every Friday from the constituents that were actually in it.
257.6-4.1%base 100 · to 2026-10-23
This week
Up most
- Will Semiconductor (OmniVision)+14.9%
- 3D Systems+10.1%
- Ambarella+7.8%
- Montage Technology+6.4%
- Power Integrations+5.6%
Down most
- AT&S-20.2%
- SCREEN Holdings-15.8%
- Siltronic-15.0%
- Tower Semiconductor-14.3%
- Aixtron-13.5%
What happened
| Date | Type | What happened | Source |
|---|---|---|---|
| 2026-10-27 | editorial note | Capex figure revised: $231M → $532MCapex moved from $231M (deep-dive-2026-08-10.md) to $532M (deep-dive-2026-10-27.md). | dossier |
| 2026-10-27 | editorial note | Margin figure revised: $7,178M → 66%Margin moved from $7,178M (deep-dive-2026-08-10.md) to 66% (deep-dive-2026-10-27.md). | dossier |
| 2026-10-27 | editorial note | Revenue figure revised: 95% → $29,591MRevenue moved from 95% (deep-dive-2026-08-10.md) to $29,591M (deep-dive-2026-10-27.md). | dossier |
| 2026-10-27 | editorial note | Verdict changed: The thesis got WIDER and the price got WORSE. Apple through 2031 and a Google long-term agreement through 2031 broaden the franchise beyond the single-program risk the last run feare…Before (deep-dive-2026-08-10.md): The thesis got WIDER and the price got WORSE. Apple through 2031 and a Google long-term agreement through 2031 broaden the franchise beyond the single-program risk the last run feared — but the stock ran +13.8% on no new quarter, forward P/E crossed ABOVE Nvidia's, the SOTP gap widened to ~17-31%, and three items the prior dossier got wrong surfaced: Hock Tan conceded Google multi-sourcing on the record, the CFO said XPUs carry LOWER margins than networking, and the "no material regulatory findings" line is void (EU VMware probe + ITC patent investigation). Still LONG the structure. But this is now a fuller-priced LONG than it was five weeks ago, and the prior seed's entire base-case target was consumed in those five weeks. After (deep-dive-2026-10-27.md): The quarter landed above its guide and the AI outlook was raised a year further out (FY27 ~$115B, FY28 line of sight ~$230B), while the share price fell from $392.16 at the call to ~$340 and the multiple compressed. Concentration rose sharply (one distributor 50% of revenue, top five ~55%), Anthropic is now guided to become the largest XPU customer in 2027, and the customer-financing layer grew again (a $63B Anthropic SPV announced today, press-release only). No XPU programme was reported re-bid or in-sourced in the window; Google's dual-sourcing at the TPU-variant level is the standing condition, unchanged. | dossier |
| 2026-10-27 | editorial note | Capex figure revised: $7,826M → $11.5 billionCapex moved from $7,826M (deep-dive-2026-08-10.md) to $11.5 billion (deep-dive-2026-10-27.md). | dossier |
| 2026-10-27 | editorial note | Margin figure revised: 85.7% → 83%Margin moved from 85.7% (deep-dive-2026-08-10.md) to 83% (deep-dive-2026-10-27.md). | dossier |
| 2026-10-27 | editorial note | Revenue figure revised: 60% → $54,229MRevenue moved from 60% (deep-dive-2026-08-10.md) to $54,229M (deep-dive-2026-10-27.md). | dossier |
| 2026-10-27 | editorial note | Verdict changed: "LONG — MEDIUM (conviction DOWN one notch from the prior MEDIUM-HIGH, on wider risk, not a worse business). At $870 the entry is the best of any pass and the operating facts got BETT…Before (deep-dive-2026-08-10.md): "LONG — MEDIUM (conviction DOWN one notch from the prior MEDIUM-HIGH, on wider risk, not a worse business). At $870 the entry is the best of any pass and the operating facts got BETTER (sold out through all of CY2027; SCA floors now quantified above the 62% all-time-peak GM and running to 2030; incumbent supply relief not landing until 2028-29). But the prior dossier's named falsifier stopped being hypothetical: CXMT was handed $8.6B on 2026-07-31 and has a Shanghai fab completing this half. It has NOT yet fired — DRAM spot rose 16.9% in July and Q3 contract prices are still up 13-18% QoQ, so the deceleration is demand-side, not a supply break. Two things the prior dossier got wrong are corrected here: it called the name regulatory-CLEAN when a US price-fixing class action against all three DRAM makers had already been filed (2026-06-30), and it never noticed FQ4'26 carries a 14th week that flatters the $50B guide by ~7.7%." After (deep-dive-2026-10-27.md): "The contract book is now on the balance sheet and in the 10-K, not just on slides. Take-or-pay with binding volumes, $134B of remaining performance obligations, $12.9B of customer deposits held to 2029-31 and $7B of letters of credit; 26 agreements covering ~35% of bit volume through 2030, with extensions negotiated and new ones priced higher. FQ4 revenue was $54.2B on a 14-week quarter, GM 86.8%. What the primary record does NOT yet show is the specific claim that calendar-2027 HBM volume is agreed: the 10-K is silent on HBM contract terms, and the 'vast majority of CY2027 HBM bit supply' line exists in this pass only in secondary recaps of prepared remarks that were not read." | dossier |
| 2026-10-27 | editorial note | Margin figure revised: 53.7% → 57%Margin moved from 53.7% (deep-dive-2026-10-05.md) to 57% (deep-dive-2026-10-27.md). | dossier |
| 2026-10-27 | editorial note | Revenue figure revised: €2,761.7M → €11.72BRevenue moved from €2,761.7M (deep-dive-2026-10-05.md) to €11.72B (deep-dive-2026-10-27.md). | dossier |
| 2026-10-27 | editorial note | Verdict changed: The earnings base has re-rated far faster than the stock. FY2026 guidance went from €34–39B to €43–45B, which puts the base FY26 EPS near €39.6 against €29 in the June dossier. On ho…Before (deep-dive-2026-10-05.md): The earnings base has re-rated far faster than the stock. FY2026 guidance went from €34–39B to €43–45B, which puts the base FY26 EPS near €39.6 against €29 in the June dossier. On house EPS, ASML trades at ~42x FY26 and ~33x FY27, down from ~57x FY26 in June (€1,656.4 ÷ €29.0), even though the share price is about the same. The new risks are an unprecedented back-end-loaded Q4 (implied €12.9–15.9B), a down-payment float that shrank in H1, and the first credible report of Chinese immersion-DUV production. The Q3 print on 14 Oct is a test of whether the Q4 load and 2027 coverage are real. Structurally still BULLISH; still WATCHING on entry. After (deep-dive-2026-10-27.md): Q3 answered the October dossier's two open tests. The Q4 load is now guided at €14.2–15.2B, a narrower and higher band than the €12.9–15.9B the old FY range implied. The down-payment float came back: non-current contract liabilities rose from €3.57B to €9.30B in one quarter, and Q3 operating cash flow was €11.8B. ASML still publishes no bookings. In their place it says, in a filed release, that its planned 2027 and 2028 supply "will not fully meet the demand". China rose to 23% of system sales from 14%. The share price fell about 13% over the same weeks, and the filings do not explain why. | dossier |
| 2026-10-27 | editorial note | Capex figure revised: $846.76B → $40.64BCapex moved from $846.76B (deep-dive-2026-09-05-refresh.md) to $40.64B (deep-dive-2026-10-27.md). | dossier |
| 2026-10-27 | editorial note | Revenue figure revised: $1,270.38 billion → $46.72BRevenue moved from $1,270.38 billion (deep-dive-2026-09-05-refresh.md) to $46.72B (deep-dive-2026-10-27.md). | dossier |
| 2026-10-27 | editorial note | Verdict changed: The Q2 beat was not a peak — July revenue accelerated to +44.7% YoY, the board appropriated a single-tranche US$29.4B of capacity capital, and H1 capex now clears the primary bar at …Before (deep-dive-2026-09-05-refresh.md): The Q2 beat was not a peak — July revenue accelerated to +44.7% YoY, the board appropriated a single-tranche US$29.4B of capacity capital, and H1 capex now clears the primary bar at US$26.8B. The thesis is unchanged and better evidenced; the only thing that moved against it is the tape, which is ~2% below the 2026-07-09 price after a beat. After (deep-dive-2026-10-27.md): The third quarter beat its own revenue guide by 2% above the top of the range, HPC reached 68% of revenue, and management said demand is "still far above" what TSMC can supply. The $52–56B capex figure this shelf carried for five passes was wrong by the time of this print — the company "reiterated" $60–64B. The new item to watch is a first stated caution on consumer and price-sensitive segments going into 2027. | dossier |
| 2026-10-26 | filing | 6-K: Company response to media report on special dividendCompany states a media report of a special dividend of about KRW 16 trillion from the Kioxia stake sale is not determined; additional shareholder return measures subject to board approval to be announced at Q3 earnings on 28 Oct 2026. | agent:company-events · SEC EDGAR 6-K |
| 2026-10-26 | filing | Form 4 cluster: 3 insiders, 20-23 Oct 2026 sales and tax withholding3 insiders filed Form 4 between 20 and 23 Oct 2026: open-market sales of 1,607 shares (Clark 869 at $51.52; Kuykendall 738 at $55.08); 9,585 shares withheld for tax at $56.54. | agent:company-events · SEC EDGAR Form 4 |
| 2026-10-26 | filing | 6-K: Treasury share acquisitions 20 Aug-21 Oct 2026Acquired 23,693,272 treasury common shares from 20 Aug to 21 Oct 2026 for KRW 40,004,339,063,500; direct treasury holding 25,319,041 shares, 3.47% of total, as of 26 Oct 2026. | agent:company-events · SEC EDGAR 6-K |
| 2026-10-26 | filing | 10-Q: Q3 2026 quarterly report, revenue $218.3mQuarter ended 30 Sep 2026: total revenue $218,289k; net income $74,565k; diluted EPS $0.69; 107,095,985 common shares outstanding at 30 Sep 2026. | agent:company-events · SEC EDGAR 10-Q |
| 2026-10-26 | guidance | 8-K: Q3 2026 results, revenue $218.3mQ3 2026 total revenue $218.3m (Q3 2025: $178.5m); GAAP diluted EPS $0.69; non-GAAP diluted EPS $0.84; Q4 2026 revenue guidance $227m-$233m. | agent:company-events · SEC EDGAR 8-K |
| 2026-10-26 | filing | 8-K: agreement to buy Besi shares, about 20% stake after purchaseOn 26 Oct 2026 Applied entered an accelerated share purchase agreement for BE Semiconductor Industries shares; with its existing holding it would own about 20% of Besi; delivery subject to HSR waiting period expiry or termination. | agent:company-events · SEC EDGAR 8-K |
Dated ahead
| Date | Company | Period | Firmness |
|---|---|---|---|
| 2026-10-28 | Amkor Technology AMKR | 2026-Q3 | expected |
| 2026-10-28 | Cadence Design Systems CDNS | 2026-Q3 | expected |
| 2026-10-28 | NXP Semiconductors NXPI | 2026-Q3 | expected |
| 2026-10-28 | Qorvo QRVO | 2026-Q3 | expected |
| 2026-10-28 | Rambus RMBS | 2026-Q3 | expected |
| 2026-10-28 | Ultra Clean Holdings UCTT | 2026-Q3 | expected |
| 2026-10-28 | SK Hynix 000660.KS | 2026-Q3 | confirmed |
| 2026-10-28 | KLA Corporation KLAC | 2026-Q3 | confirmed |
| 2026-10-28 | Silicon Laboratories SLAB | 2026-Q4 | expected |
| 2026-10-28 | FormFactor FORM | 2026-Q3 | expected |
| 2026-10-28 | Wolfspeed WOLF | 2026-Q3 | expected |
| 2026-10-28 | Amphenol APH | 2026-Q3 | confirmed |
| 2026-10-28 | Impinj PI | 2026-Q3 | confirmed |
| 2026-10-28 | United Microelectronics UMC | 2026-Q3 | confirmed |
| 2026-10-29 | FormFactor FORM | 2026-Q3 | expected |
| 2026-10-29 | Impinj PI | 2026-Q3 | expected |
| 2026-10-29 | KLA Corporation KLAC | 2026-Q3 | expected |
| 2026-10-29 | Lam Research LRCX | 2026-Q3 | expected |
| 2026-10-29 | Teradyne TER | 2026-Q3 | expected |
| 2026-10-29 | Allegro MicroSystems ALGM | FY2027-Q2 | expected |